NO20043832L - Oral fast losningsformulering av en darlig vannloselig aktiv substans - Google Patents

Oral fast losningsformulering av en darlig vannloselig aktiv substans

Info

Publication number
NO20043832L
NO20043832L NO20043832A NO20043832A NO20043832L NO 20043832 L NO20043832 L NO 20043832L NO 20043832 A NO20043832 A NO 20043832A NO 20043832 A NO20043832 A NO 20043832A NO 20043832 L NO20043832 L NO 20043832L
Authority
NO
Norway
Prior art keywords
active substance
solid solution
poorly water
oral solid
soluble active
Prior art date
Application number
NO20043832A
Other languages
English (en)
Inventor
Henricus R M Gorissen
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20043832L publication Critical patent/NO20043832L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20043832A 2002-02-14 2004-09-13 Oral fast losningsformulering av en darlig vannloselig aktiv substans NO20043832L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02075623 2002-02-14
PCT/EP2003/050014 WO2003068266A1 (en) 2002-02-14 2003-02-11 Oral solid solution formulation of a poorly water-soluble active substance

Publications (1)

Publication Number Publication Date
NO20043832L true NO20043832L (no) 2004-09-13

Family

ID=27619166

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043832A NO20043832L (no) 2002-02-14 2004-09-13 Oral fast losningsformulering av en darlig vannloselig aktiv substans

Country Status (25)

Country Link
US (2) US20050008697A1 (no)
EP (1) EP1476196B1 (no)
JP (1) JP2005517041A (no)
KR (1) KR101014545B1 (no)
CN (1) CN1273194C (no)
AR (1) AR038681A1 (no)
AT (1) ATE345817T1 (no)
AU (1) AU2003208713B2 (no)
BR (1) BR0307278A (no)
CA (1) CA2472744A1 (no)
DE (1) DE60309839T2 (no)
DK (1) DK1476196T3 (no)
ES (1) ES2277635T3 (no)
HK (1) HK1077218A1 (no)
HR (1) HRP20040613A2 (no)
IL (2) IL162883A0 (no)
MX (1) MXPA04007852A (no)
NO (1) NO20043832L (no)
PL (1) PL370452A1 (no)
PT (1) PT1476196E (no)
RU (1) RU2314811C2 (no)
SI (1) SI1476196T1 (no)
UA (1) UA79267C2 (no)
WO (1) WO2003068266A1 (no)
ZA (1) ZA200405608B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
TW200633713A (en) * 2004-12-23 2006-10-01 Solvay Pharm Bv Oral immediate release formulation of a poorly water-soluble active substance
WO2007054975A1 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2007308479A (ja) 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 固体分散体製剤
WO2007144418A1 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Oral pharmaceutical composition of a poorly water-soluble active substance
KR20090033246A (ko) * 2006-06-22 2009-04-01 솔베이 파마슈티칼스 비. 브이 수용성이 불량한 활성 물질의 경구용 약제학적 조성물
AU2007271088A1 (en) * 2006-07-06 2008-01-10 Ares Trading S.A. An oral pharmaceutical composition of an anilinopyrimidine, its preparation and use thereof
CA2662315A1 (en) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Solid composites of a calcium receptor-active compound
AR071375A1 (es) * 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
CA2765033C (en) * 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
HUE039328T2 (hu) 2010-08-04 2018-12-28 Gruenenthal Gmbh 6'-Fluor-(N-metil- vagy N,N-dimetil-)-4-fenil-4',9'-dihidro-3'H-spiro[ciklohexán-1,1'pirano[3,4,B]indol]-4-amin összetételû gyógyszerészeti adagolási forma a neuropátiás fájdalom kezelésére
KR101828768B1 (ko) * 2010-08-04 2018-02-13 그뤼넨탈 게엠베하 6’­플루오로­(N­메틸­ 또는 N,N­디메틸­)­4­페닐­4’,9’­디하이드로­3’H­스피로[사이클로헥산­1,1’­피라노[3,4,b]인돌]­4­아민을 포함하는 약제학적 투여형
US20180185399A1 (en) * 2015-07-03 2018-07-05 Zhejiang Hisun Pharmaceutical Co., Ltd. Ginsenoside c-k oral solid preparation and preparation method thereof
PL424452A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
WO2020112961A1 (en) 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3359167A (en) * 1965-07-22 1967-12-19 Pfizer & Co C Vitamin a compositions
US4325970A (en) * 1980-10-09 1982-04-20 Hoffmann-La Roche Inc. 15-Acetyl-prostaglandins
NZ224497A (en) * 1987-05-18 1990-04-26 Janssen Pharmaceutica Nv Pharmaceutical composition comprising flunarizine
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
ES2229473T3 (es) * 1997-01-30 2005-04-16 Novartis Ag Composiciones farmaceuticas sin aceite que contienen ciclosporina a.
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions

Also Published As

Publication number Publication date
CN1633307A (zh) 2005-06-29
PL370452A1 (en) 2005-05-30
IL162883A (en) 2009-05-04
AU2003208713A1 (en) 2003-09-04
WO2003068266A1 (en) 2003-08-21
EP1476196A1 (en) 2004-11-17
EP1476196B1 (en) 2006-11-22
CN1273194C (zh) 2006-09-06
KR20040085193A (ko) 2004-10-07
IL162883A0 (en) 2005-11-20
DE60309839D1 (de) 2007-01-04
KR101014545B1 (ko) 2011-02-16
BR0307278A (pt) 2004-12-28
CA2472744A1 (en) 2003-08-21
DK1476196T3 (da) 2007-03-05
JP2005517041A (ja) 2005-06-09
US20050008697A1 (en) 2005-01-13
AR038681A1 (es) 2005-01-26
HRP20040613A2 (en) 2005-04-30
HK1077218A1 (en) 2006-02-10
UA79267C2 (en) 2007-06-11
ZA200405608B (en) 2005-06-24
RU2314811C2 (ru) 2008-01-20
US20110086844A1 (en) 2011-04-14
AU2003208713B2 (en) 2007-10-18
SI1476196T1 (sl) 2007-04-30
MXPA04007852A (es) 2004-10-15
DE60309839T2 (de) 2007-03-15
RU2004127457A (ru) 2005-04-20
ES2277635T3 (es) 2007-07-16
PT1476196E (pt) 2007-02-28
ATE345817T1 (de) 2006-12-15
AU2003208713B9 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
NO20043832L (no) Oral fast losningsformulering av en darlig vannloselig aktiv substans
FI7617U1 (fi) Amorfisen aktiivisen ainesosan stabiloitu farmaseuttinen valmiste
NO20043866L (no) Farmasoytisk formulering av IRESSA omfattende et vannopploselig cellulosederivat
ATE372765T1 (de) Feste pharmazeutische formulierungen mit telmisartan
NO20053076D0 (no) Farmasoytisk formulering med en uloselig aktiv forbindelse.
CY2018005I1 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
DK2258394T3 (da) Oral doseringsform omfattende en PDE 4-inhibitor som en aktiv bestanddel og polyvinylpyrrolidon som excipiens
NO20033343L (no) Farmasöytiske doseringsformer av epothiloner for oral administrasjon
PT1501534E (pt) Formulacoes farmaceuticas
AU2003229555A1 (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
NO20042842L (no) Farmasoytiske formuleringer av platina-derivat
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
NO20026209L (no) Endoparasitticidale midler for frivillig oralt inntak av dyr
AU2003208761A1 (en) A method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use
DK1624869T3 (da) Doseringsform indeholdende pantoprazol som aktiv bestanddel
DE60336999D1 (de) Melatonin enthaltende pharmazeutische formulierung
FR2852845B1 (fr) Compositions pharmaceutiques a activite antibiotique
PL1848439T3 (pl) Doustna formulacja o natychmiastowym uwalnianiu słabo rozpuszczalnej w wodzie substancji aktywnej
DK1666473T3 (da) Carboxylsyreforbindelser og medicinske sammensætninger indeholdende samme som aktiv ingrediens
NO20043633L (no) Oral doseringsform for kontrollert medikamentfrigivning
DE502004003170D1 (de) Schmelzformulierte, multipartikuläre orale darreichungsform enthaltend clavulansäure
AU2003244259A1 (en) Oral injectable pharmaceutical composition comprising florfenicol as an active ingredient
NO20032581D0 (no) Farmasöytisk formulering av gepiron for oral administrering
AU2003302888A1 (en) Oral formulations for poorly absorptive hydrophilic drugs
IL183554A0 (en) Oral immediate formulation of a poorly watersoluble active substance

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application